Orgenesis Inc.

ORGS Healthcare Biotechnology

Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023.

Revenue
+82.4%
EPS
−104.5%
Free cash flow
−317.9%

Quarter to December 2024, against a year earlier

0.35 0.05 −12.50%
Market cap
$5.7M
P/E
0.0×
Fwd P/E
1.0×
Dividend yield
—
F-score
3/9
Altman Z
−352.42
Beneish M
n/a
Dividend safety
n/a
Older periods Mar '24 Jun '24 Sep '24 Dec '24
Piotroski F-Score

+8 more TTM periods

1 4 3 3
ROE
478.19% 203.46% 175.12% 164.62%
ROA
(79.92%) (119.30%) (145.76%) (605.73%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
393.45% 215.72% 184.72% 188.28%
Average Days of Receivables
169.05 132.33 65.37 14.11
Free Cash Flow per Share
(3.93) (3.23) (3.34) (4.12)
Free Cash Flow
(13.05) (12.54) (15.74) (17.34)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026